Biotech Values

[orangeone]

Thanks Iwfal. Sounds reasonable...My concern was that somehow that even if they maintain exisitng market share, an AG must somehow offer a lower pricing (which Sandoz will have to match), otherwise what is the point of having two products, neither of which is supported by any marketing? (or is there still some residual marketing with the brand?) I agree a natural equilibrium should result if Ampha does not arrive, and I would otherwise be happy in principle if Sanofi is signalling threats to Ampha, if Mnta were not just a bystander in the economics of all this.

Thanks a lot for postings regarding the suit. Interesting reading for me (you are right i am a patent atty, but a European one). Looking fwd to exchanging thoughts on all this...

Cheers,